Optimizing anti-TNF treatments in inflammatory bowel disease.
about
Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel diseaseBenefit-risk assessment of golimumab in the treatment of refractory ulcerative colitisCurrent stage in inflammatory bowel disease: What is next?Pharmacologic therapy for inflammatory bowel disease refractory to steroidsTherapeutic drug monitoring in inflammatory bowel diseaseWithdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel diseaseRedeeming an old foe: protective as well as pathophysiological roles for tumor necrosis factor in inflammatory bowel diseaseExperience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseasesThe safety of vedolizumab for the treatment of ulcerative colitis.Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study.Electroacupuncture improves trinitrobenzene sulfonic Acid-induced colitis, evaluated by transcriptomic studyTumour necrosis factor superfamily members in the pathogenesis of inflammatory bowel diseaseAdalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta-analysis.Optimizing the use of anti-tumor necrosis factor in the management of patients with Crohn's disease.Molecular and biochemical characterization of recombinant guinea pig tumor necrosis factor-alphaA novel anti-TNF scFv constructed with human antibody frameworks and antagonistic peptides.Interferon Gamma Counteracts the Angiogenic Switch and Induces Vascular Permeability in Dextran Sulfate Sodium Colitis in Mice.Neutrophil-to-Lymphocyte Ratio for Predicting Loss of Response to Infliximab in Ulcerative ColitisGenetic basis of TNF-α antagonist associated psoriasis in inflammatory bowel diseases: a genotype-phenotype analysis.Smoking is Associated With Extra-intestinal Manifestations in Inflammatory Bowel Disease.Intestinal healing after anti-TNF induction therapy predicts long-term response to one-year treatment in patients with ileocolonic Crohn's disease naive to anti-TNF agents.AHR Activation Is Protective against Colitis Driven by T Cells in Humanized MiceSecond Korean guidelines for the management of Crohn's disease.Management of Crohn's disease in poor responders to adalimumab.Tailoring anti-TNF therapy in IBD: drug levels and disease activity.The use of prognostic factors in inflammatory bowel diseases.The role of integrin antagonists in the treatment of inflammatory bowel disease.Biological therapy for ulcerative colitis: an update.Molecular Analysis of Inflammatory Bowel Disease: Clinically Useful Tools for Diagnosis, Response Prediction, and Monitoring of Targeted Therapy.Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy.Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF-α experience to oncology.New Insights into the Mechanisms of Action of Anti-Tumor Necrosis Factor-α Monoclonal Antibodies in Inflammatory Bowel Disease.Use of anti-TNF drug levels to optimise patient management.Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management.Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window.Anti-TNF-α therapies for the treatment of Crohn's disease: the past, present and future.Emerging therapeutic targets and strategies in Crohn's disease.Incidence of and Predictors for Early Discontinuation of Biological Therapies in Veteran Patients with Inflammatory Bowel Disease.Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance.
P2860
Q26745721-FF67EAEE-B5D4-4DDE-B8BE-5346DC5F2341Q26764801-248D22F2-EC8C-4224-8292-C235BAB70E05Q26777429-837DC0D8-8BC3-43D6-B5FC-C6CF85A2B385Q26796415-C4DFAE06-3F99-46D0-A138-9211E75A6C7AQ26852729-F7911F76-AF6D-4B10-93D4-C8F3950746A9Q26866281-B829EDD9-66A8-468A-828D-0BF01222823DQ27027630-E0709921-81B2-4A89-B270-AE2AA3DE9C9FQ28066776-C2A07639-DFD2-45BE-9A04-FA67D590ADF1Q30235363-36C4FE3F-F119-4FA6-9715-C86324838589Q31113830-06525051-4BF9-4DE5-B35B-2BF889452708Q33796809-E6737EAD-FBE5-4A48-9A7C-8F57E294E059Q33865593-419644CC-3413-4466-8ADF-0C0EAA27A266Q35213972-6C779F73-B5CC-4290-BDA1-6894F4FD0B01Q35561386-131A0245-51CC-401E-9938-91515FE71BC2Q35592437-7D9EB60E-03E6-4E17-AAE1-833C9AC4B9E8Q35658998-3AAA611C-92C0-487F-9146-DBC81DC552EEQ35688870-A1171AEF-AAA4-4E0E-8735-8E60039CCEEFQ36246295-96DFE5BB-9605-4166-A160-1EBBB7BB807BQ36586054-C4FBEBF7-3E26-48FC-813B-4330A9C07324Q37098416-8E408BAC-AF7E-4E18-BA13-6E68DF9FAB84Q37306556-9EC05164-C256-41F9-905A-88FDA160190BQ37410541-6957F945-6214-4FCA-9ED3-0F0AD54ADBE3Q37662498-244C4D32-2955-4F5D-9F58-A42FD260D7F1Q37708656-9A58D9E7-9F4C-4656-9BAC-18B33E4974C8Q38176154-BC34F819-1AFD-4D43-AE0B-23CD9DACCEEBQ38254878-91B33F67-4FB6-4D75-9FC4-52D5B527B7C4Q38257410-6B1813F4-C6E4-4A72-BA9D-37DD72991BB1Q38259532-EC4FDCF0-353C-4D4F-9513-FF1257727F14Q38492052-79C4688D-3821-4A35-9717-517793C25BBAQ38501680-B5B44FE5-24AE-49B0-A153-2E530146A0D0Q38527999-816FC8E6-E743-46FB-B3E8-A1D86B0E07F5Q38564877-4F1DC415-3B31-4214-901A-09F23F171589Q38582765-0B80B57C-A95E-4E9E-8BC2-C786880956ADQ38608951-C6036D23-C133-45B4-B27D-A7B90FFD2508Q38619950-DE6625CD-355A-4FF3-970F-EDE007B5D70EQ38620415-25240E6A-8887-43C9-8BF9-72D8A26223EDQ38652276-1407377F-4F8A-41C8-A6DD-4950CB905885Q38696392-7E866DAF-C1CC-440C-B8BB-3D76C0744430Q38750962-5F7929FC-D539-442E-8938-587FD8E24CD4Q38789642-EF06D4EC-F6E1-4DC8-8758-9554FDC2C8C9
P2860
Optimizing anti-TNF treatments in inflammatory bowel disease.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Optimizing anti-TNF treatments in inflammatory bowel disease.
@en
type
label
Optimizing anti-TNF treatments in inflammatory bowel disease.
@en
prefLabel
Optimizing anti-TNF treatments in inflammatory bowel disease.
@en
P921
P1433
P1476
Optimizing anti-TNF treatments in inflammatory bowel disease.
@en
P2093
Shomron Ben-Horin
Yehuda Chowers
P356
10.1016/J.AUTREV.2013.06.002
P50
P577
2013-06-19T00:00:00Z